Filana Therapeutics (STU:PX91) E10: €-1.33 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PX91 Filana Therapeutics Inc STU:PX91
37 GF Score
Price €0.78
! 2 Warning Signs
View Full Analysis

What is Filana Therapeutics E10?

Filana Therapeutics STU:PX91 -4.29% 37 E10 is €-1.33 as of Mar. 2026. GuruFocus rates STU:PX91 with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Filana Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.182. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.33 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was -23.50% per year. During the past 5 years, the average E10 Growth Rate was -26.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Filana Therapeutics was 36.70% per year. The lowest was -40.60% per year. And the median was -9.50% per year.

As of today (2026-07-25), Filana Therapeutics's current stock price is €0.781. Filana Therapeutics's E10 for the quarter that ended in Mar. 2026 was €-1.33. Filana Therapeutics's Shiller PE Ratio of today is .


Filana Therapeutics  (STU:PX91) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Filana Therapeutics E10 Related Terms


Filana Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Filana Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Filana Therapeutics E10 Chart

Filana Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.61 -0.78 -1.57 -1.67 -1.41

Filana Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.59 -1.48 -1.53 -1.41 -1.33

STU:PX91 vs BOLD, INKT, XLO: E10 Comparison

For the Biotechnology subindustry, Filana Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Filana Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Filana Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Filana Therapeutics's Shiller PE Ratio falls into.


STU:PX91
37GF Score
Filana Therapeutics Inc STU:PX91
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Filana Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Filana Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.182/330.2130*330.2130
=-0.182

Current CPI (Mar. 2026) = 330.2130.

Filana Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201606 -0.409 241.018 -0.560
201609 -0.481 241.428 -0.658
201612 -0.398 241.432 -0.544
201703 -0.393 243.801 -0.532
201706 -0.570 244.955 -0.768
201709 -0.336 246.819 -0.450
201712 -0.313 246.524 -0.419
201803 -0.268 249.554 -0.355
201806 -0.308 251.989 -0.404
201809 -0.094 252.439 -0.123
201812 -0.035 251.233 -0.046
201903 -0.071 254.202 -0.092
201906 -0.053 256.143 -0.068
201909 -0.036 256.759 -0.046
201912 -0.072 256.974 -0.093
202003 -0.045 258.115 -0.058
202006 -0.044 257.797 -0.056
202009 -0.051 260.280 -0.065
202012 -0.074 260.474 -0.094
202103 -0.076 264.877 -0.095
202106 -0.108 271.696 -0.131
202109 -0.204 274.310 -0.246
202112 -0.310 278.802 -0.367
202203 -0.400 287.504 -0.459
202206 -0.454 296.311 -0.506
202209 -0.515 296.808 -0.573
202212 -0.444 296.797 -0.494
202303 -0.542 301.836 -0.593
202306 -0.581 305.109 -0.629
202309 -0.572 307.789 -0.614
202312 -0.458 306.746 -0.493
202403 -0.396 312.332 -0.419
202406 0.121 314.175 0.127
202409 -0.523 315.301 -0.548
202412 -0.544 315.605 -0.569
202503 -0.444 319.799 -0.458
202506 -0.798 322.561 -0.817
202509 -0.187 324.800 -0.190
202512 -0.222 324.054 -0.226
202603 -0.182 330.213 -0.182

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1.33 mean?
Filana Therapeutics (STU:PX91) has a E10 of €-1.33 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Filana Therapeutics and its competitors.
Is Filana Therapeutics' E10 too high?
Filana Therapeutics' current E10 is €-1.33. Overall, Filana Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Filana Therapeutics' E10 compare to BOLD and INKT?
Filana Therapeutics' E10 of €-1.33 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Filana Therapeutics and its competitors. Filana Therapeutics's current E10 is €-1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Filana Therapeutics stock overvalued right now?
Filana Therapeutics (STU:PX91) has a current E10 of €-1.33. The current E10 is €-1.33. Filana Therapeutics' overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Filana Therapeutics (STU:PX91), the current E10 is €-1.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Filana Therapeutics Business Description

Address 6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
37GF Score

Get the complete analysis for STU:PX91

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.78
Price